NWPF

News Archives

Filtered by: September 2005

Azilect can provide significant additional benefits to levodopa treated Parkinson’s Disease patients

Friday September 30, 2005

New data presented in an oral presentation session, at the 9th congress of the European Federation of Neurological Societies, showed that treatment with Azilect (rasagiline 1 mg) once daily can provide significant additional benefits to levodopa treated patients with moderate to advanced Parkinson’s disease (PD). These benefits were seen regardless of whether patients were receiving additional, optimized treatment with a dopamine agonist.

Read Article

Low cholesterol linked to Parkinson’s risk in men

Thursday September 29, 2005

Is it possible to have too low a level of cholesterol? A cholesterol profile that reduces the risk of heart disease may increase the risk for Parkinson’s disease — at least for men — researchers report.

Read Article

Ali’s daughter shares book on Parkinson’s Disease

Wednesday September 28, 2005

You only have to say his name and most everyone will know who he is.

Muhammad Ali is legendary in the ring, but the three time world heavyweight champion is a long way from that.

Read Article

Ceregene initiates gene therapy trial in Parkinson’s

Wednesday September 28, 2005

The goal of the study is to determine the safety and efficacy of the treatment. Efficacy will be measured by standardized tests for Parkinson’s patients, as well as brain imaging studies.

Read Article

Brain inflammation ’initiates’ Parkinson’s

Wednesday September 28, 2005

Researchers in Sydney say they have made a significant discovery about Parkinson’s disease.

The Prince of Wales Medical Research Institute says it has found that the immune system plays a role in the development of the disease by attacking parts of the brain.

Read Article

Neurologix announces positive results of gene therapy clinical trial in Parkinson’s disease

Wednesday September 28, 2005

Neurologix’s Phase I trial showed positive interim results in patients with Parkinson’s disease. One year following treatment, patients exhibited a statistically significant improvement in motor function on the side of their body correlating to the treated part of the brain. Further, PET scans at one year revealed that the treated side of the brain exhibited a statistically significant decrease in abnormal metabolism, results considered similar to those achieved with STN Deep Brain Stimulation.

Read Article

Parkinson’s drugs may trigger gambling obsession

Tuesday September 20, 2005

Recent reports suggest that pathologic gambling, a severe addiction to gambling, is a rare complication of using anti-Parkinson’s drugs. Now, new research delves deeper into this association and reveals that the gambling may resolve when the drug is stopped and that the drug pramipexole is often implicated.

Read Article

Parkinson’s Patient Advocates Call on Amgen to Move Forward with GDNF Clinical Trials

Tuesday September 20, 2005

Sunday’s CBS News program "60 Minutes" profiled several courageous Parkinson’s patients who volunteered for Amgen, Inc.’s clinical trials of glial cell line-derived neurotrophic factor (GDNF), a promising Parkinson’s treatment for which the biotech giant company holds the patent. Today, Tuesday, September 13, 2005, a coalition of grassroots Parkinson’s patients and organizations published an open letter to Amgen President and CEO Kevin Sharer in a full-page ad in the Ventura County Star, where Amgen is headquartered, urging him to restart human trials of the growth factor or license it to a company that will.

Read Article

Phase III Date for Rotigotine in Advanced Parkinson’s Disease at EFNS Congress

Tuesday September 20, 2005

MONHEIM, Germany, Sept. 19, 2005 - SCHWARZ PHARMA will release a broad spectrum of clinical and pre-clinical data at the 9th European Federation of Neurological Societies (EFNS) in Athens. Most importantly, the results of a phase III trial conducted in the U.S. with rotigotine transdermal system for the treatment of patients with advanced-stage Parkinson’s disease will be shared for the first time.

Read Article

Drug nerve infusion reversed Parkinson’s brain damage

Tuesday September 20, 2005

Neuroscientists at Frenchay hospital in Bristol have reported that the drug GDNF (glial cell line-derived neurotrophic factor) reversed Parkinsons and helped regenerate nerve fibres in a region of the brain called the putamen, which is responsible for the chemical dopamine, crucial for brain cell communication. The findings were reported in Nature Medicine following an autopsy on a Parkinson’s patient’s brain, who had receiving the drug but died of an unrelated heart attack.

Read Article
<< Back 1 - 10 of 34 Next >>

Recent News

Nov 17 - 'Moving Day' participant is not letting young-onset Parkinson's disease stop him
Nov 17 - Focused ultrasound shows promise for treating Parkinson's tremor
Nov 17 - New research to target air pollution as a potential trigger for Parkinson’s
Nov 17 - This device will let you feel what it's like to suffer from Parkinson's
Nov 10 - How does Parkinson's disease influence depression?
Nov 10 - House votes to repeal ObamaCare's Medicare cost-cutting board
Nov 10 - Microsoft shows off watch that quiets Parkinson's tremors
Nov 3 - Utah group battling Parkinson's disease with boxing
Nov 3 - UVA-LED STUDY EXAMINES POTENTIAL OF SOUND WAVES TO MANAGE PARKINSON’S DISEASE
Oct 27 - Herbicide's link to Parkinson's disease
Oct 27 - NTU Singapore, KAIST scientists discover new mechanism that causes Parkinsonian symptoms
Oct 27 - 70,000 Washingtonians face higher insurance costs after Trump order, officials say
Oct 18 - Brain disconnections may contribute to Parkinson's hallucinations
Oct 18 - Fighting Parkinson's disease through dance
Oct 17 - Scientists Identify Structure of PINK1, Key Parkinson’s-protective Protein
Oct 17 - Diabetes drug cuts Parkinson's risk by 28 percent, study finds
Oct 10 - Advances in Brain Pacemaker Reduces Tremors, Helps Parkinson's Sufferers Live a More Normal Life
Oct 10 - Medical History Could Help Predict Parkinson's Disease Risk Long Before Diagnosis
Oct 3 - Changes in Olfactory Bulb Explain Loss of Smell in Early Stages of Parkinson’s Disease, Study Finds
Oct 3 - Sleep Disturbances May Worsen Motor Symptoms in Parkinson’s Disease, Study Suggests